Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 77 The GLP-1 segment accounts for 16% of total diabetes care market value in North America North America GLP-1 market GLP-1 value in bDKK Victoza® Dulaglutide OzempicⓇ Other Exenatide Share of total diabetes care • 60 market 14% 12% 50 CAGR value¹: 38.0% 10% 40- 8% • 30 6% 10 20- 10 4% 2% 0 0% Aug 2013 Aug 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT Aug, 2018 value figures (DKK) changing diabetes® Key observations for VictozaⓇ and Ozempic® in the USA VictozaⓇ and OzempicⓇ value market share within the GLP-1 segment is 45%² Around 94% of new patients who start on VictozaⓇ transition from outside of GLP-1 segment. Around 71% of new patients who start on OzempicⓇ transition from outside of GLP-1 segment³ Unrestricted access for OzempicⓇ is more than 2/3 for Commercial and Medicare Part D combined Around 70% of VictozaⓇ prescriptions are for the higher dose 1.8 mg. Around 36% of OzempicⓇ prescriptions are for the higher dose 1 mg4 2 Source: IQVIA NSP monthly, MAT Aug, 2018 3 IQVIA SOB, week 14 September 2018 (based on 4 week average) 4 IQVIA, NPA, August 2018 novo nordisk

View entire presentation